# Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients

> **NCT04621123** · PHASE2 · COMPLETED · sponsor: **Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia** · enrollment: 384 (actual)

## Conditions studied

- SARS-CoV-2 Infection
- Safety and Efficacy

## Interventions

- **BIOLOGICAL:** Convalescent anti-SARS-CoV-2 MBT plasma
- **OTHER:** Control Group

## Key facts

- **NCT ID:** NCT04621123
- **Lead sponsor:** Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-10
- **Primary completion:** 2021-05-31
- **Final completion:** 2021-07-28
- **Target enrollment:** 384 (ACTUAL)
- **Last updated:** 2021-09-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04621123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04621123, "Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04621123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*